The AEZS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AEZS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The AEZS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View AEZS Detailed Price Forecast - CNN Money||View AEZS Detailed Summary - Google Finance|
|View AEZS Detailed Summary - Yahoo! Finance||View AEZS Stock Research & Analysis - Zacks.com|
|View AEZS Trends & Analysis - Trade-Ideas||View AEZS Major Holders - Barrons|
|View AEZS Call Transcripts - NASDAQ||View AEZS Breaking News & Analysis - Seeking Alpha|
|View AEZS Annual Report - CompanySpotlight.com||View AEZS OTC Short Report - OTCShortReport.com|
|View AEZS Fundamentals - TradeKing||View AEZS SEC Filings - Bar Chart|
|View Historical Prices for AEZS - The WSJ||View Performance/Total Return for AEZS - Morningstar|
|View the Analyst Estimates for AEZS - MarketWatch||View the Earnings History for AEZS - CNBC|
|View the AEZS Earnings - StockMarketWatch||View AEZS Buy or Sell Recommendations - MacroAxis|
|View the AEZS Bullish Patterns - American Bulls||View AEZS Short Pain Metrics - ShortPainBot.com|
|View AEZS Stock Mentions - StockTwits||View AEZS Stock Mentions - PennyStockTweets|
|View AEZS Stock Mentions - Twitter||View AEZS Investment Forum News - Investor Hub|
|View AEZS Stock Mentions - Yahoo! Message Board||View AEZS Stock Mentions - Seeking Alpha|
|View Insider Transactions for AEZS - SECform4.com||View Insider Transactions for AEZS - Insider Cow|
|View AEZS Major Holdings Summary - CNBC||View Insider Disclosure for AEZS - OTC Markets|
|View Insider Transactions for AEZS - Yahoo! Finance||View Institutional Holdings for AEZS - NASDAQ|
|View AEZS Stock Insight & Charts - FinViz.com||View AEZS Investment Charts - StockCharts.com|
|View AEZS Stock Overview & Charts - BarChart||View AEZS User Generated Charts - Trading View|
Aeterna Zentaris: 4Q Earnings Snapshot
Posted on Tuesday March 26, 2019
The Summerville, South Carolina-based company said it had a loss of 31 cents per share. The drug developer posted revenue of $1.4 million in the period. For the year, the company reported net income of ...
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results
Posted on Tuesday March 26, 2019
Aeterna Zentaris Inc. (AEZS) (AEZS) today reported its financial and operating results for the fourth quarter and year ended December 31, 2018. The increase in total revenue in 2018 relates to license fees, royalty income and product sales associated with executing the License and Assignment Agreement for Macrilen™ (macimorelin) in January 2018.
Aeterna Zentaris to Announce Fourth Quarter and Year End 2018 Financial and Operating Results on March 26, 2019
Posted on Tuesday March 19, 2019
Aeterna Zentaris Inc. (AEZS) (AEZS) will announce its fourth quarter and year ended December 31, 2018 financial and operating results after market close on Tuesday, March 26, 2019. Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on commercializing novel pharmaceutical therapies, principally through out-licensing arrangements. Aeterna Zentaris is a party to a license and assignment agreement with a subsidiary of Novo Nordisk A/S to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada.
Aeterna Zentaris (AEZS) Moves to Buy: Rationale Behind the Upgrade
Posted on Monday March 18, 2019
Aeterna Zentaris (AEZS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).